"PVS-RIPO, the prototype oncolytic poliovirus recombinant, was FDA approved under an Investigator-initiated Investigational New Drug application (IND no. 14,735

"PVS-RIPO, the prototype oncolytic poliovirus recombinant, was FDA approved under an Investigator-initiated Investigational New Drug application (IND no. 14,735). Clinical trials in patients with glioblastoma multiforme are currently recruiting patients (clinicaltrials.gov trial no. NCT01491893)." http://neuro.surgery.duke.edu/gromeier http://neuro.surgery.duke.edu/gromeier